Catalent, Inc.
Catalent, Inc. (CTLT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctlt · pe ratio · data through Jun 30, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Catalent, Inc. (CTLT) measures how much investors pay for each dollar of the company's trailing earnings. CTLT's current PE ratio of N/A is calculated by dividing its stock price of $63.48 by its TTM earnings per share of -$5.76.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-06-30
PE Ratio History
2011 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 9 fiscal years · Front-end computedMinQ1 · 25%40.0x
MedianQ3 · 75%144.7x
Max
At N/A, CTLT's current P/E is lower than in 0% of its annual fiscal year readings over the past 9 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Catalent, Inc.You CTLT | $11.5B | N/A | — | -$5.76 |
 Becton, Dickinson and Company BDX | $54.4B | 25.13x | -28.8% | $5.85 |
 Cerevel Therapeutics Holdings, Inc. CERE | $8.2B | N/A | — | -$2.67 |
 Intra-Cellular Therapies, Inc. ITCI | $14.0B | N/A | — | -$0.72 |
 Karuna Therapeutics, Inc. KRTX | $12.6B | N/A | — | -$11.73 |
 Oak Street Health, Inc. OSH | $9.5B | N/A | — | -$2.21 |
 Revvity, Inc. RVTY | $11.2B | 45.49x | +28.8% | $2.13 |
Industry Average 2 peers with valid PE | — | 35.31x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-06-30Latest FY2024 | — | $-5.76 | — | |
2023-06-30 FY2023 | — | $-1.28 | — | |
2022-06-30 FY2022 | 37.84x | $2.84 | +21.9% | |
2021-06-30 FY2021 | 31.05x | $3.48 | -51.1% | |
2020-06-30 FY2020 | 63.47x | $1.15 | +10.5% | |
2019-06-30 FY2019 | 57.44x | $0.95 | -12.6% | |
2018-06-30 FY2018 | 65.74x | $0.64 | +64.5% | |
2017-06-30 FY2017 | 39.96x | $0.88 | +55.3% | |
2016-06-30 FY2016 | 25.73x | $0.89 | +55.3% | |
2015-06-30 FY2015 | 16.57x | $1.77 | -88.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Catalent, Inc. (CTLT) measures how much investors pay for each dollar of the company's trailing earnings. CTLT's current PE ratio of N/A is calculated by dividing its stock price of $63.48 by its TTM earnings per share of -$5.76.
Frequently asked questions
CTLT pe ratio · 6 questionsCTLT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $63.48 and TTM EPS of -$5.76. Data sourced from Financial Modeling Prep via CTLT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Catalent, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09